Inve India ▾

AstraZeneca Pharma India share price & results

AstraZeneca Pharma India Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY26
Ownership as of
Sept 2026

Indian arm of global AstraZeneca; markets Oncology, Biopharmaceuticals and Rare Disease medicines.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue683 ₹ crore+29.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin7.0 %−8.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit38.0 ₹ crore−32.1% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity21.16 %−0.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-0.81 %−4.5 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)31.23 %+0.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

2 of 5 judged targets kept · 3 open · verdicts reflect calls analysed to Q1 FY26.

AstraZeneca Pharma India Limited management guidance track record on Inve: 8 targets tracked across analysed earnings calls (2 achieved, 3 missed, 3 open).

TargetOriginal wordingSaidLatest callVerdict
Dividend Payout RatioIncrease towards 50%Q1 FY23Q1 FY26:Dividend of ₹32/share on EPS of ₹46.3 results in a payout ratio of 69.1%, significantly exceeding the 50% target.
Call transcript, Q1 FY26 · 14 Aug 2025		Achieved
Consolidated Revenue Target$1 billion by FY30Q1 FY22Q1 FY26:Analyst mentions the 'billion dollar' vision, but management does not re-commit to the specific target or timeline, only referencing the past Chairman's vision.
Call transcript, Q1 FY26 · 14 Aug 2025		Ghosted
Bangalore Plant Sale RealizationCompletion of sale in next 12 to 15 months
Call transcript, Q1 FY25 · 8 Aug 2024		Q1 FY25Q1 FY26:The call (12 months later) discusses the one-off costs associated with the plant closure but does not confirm the completion of the sale.
Call transcript, Q1 FY26 · 14 Aug 2025		At Risk

Source: Inve Guidance Tracker for AstraZeneca Pharma India Limited · to Q1 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of AstraZeneca Pharma India Limited's 8 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 5 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹6,073 +0.36% · +₹21.5

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −34.7% 1Y

₹6k₹7k₹8k₹9k₹10kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹9,302.5 on 24 Oct 2025 → ₹6,073. High ₹9,827.5 (3 Nov 2025), low ₹5,719.5 (8 Oct 2026).

Previous close
₹6,051.5
Market cap
₹15.1k Cr
52-week range
₹5,719.5 – ₹9,827.5
One year
−34.78%
Price to earnings (TTM to Jun 2026)
86.99×
Return on equity (TTM to Jun 2026)
21.16%

Overview

Symbol
NSE:ASTRAZEN
Exchange
NSE
Currency
INR

What AstraZeneca Pharma India Limited does

Based on the company's own presentations, annual report and earnings calls.

AstraZeneca Pharma India Limited is the Indian listed subsidiary of the UK-headquartered AstraZeneca group, engaged in the marketing and commercialisation of specialist prescription medicines developed by the global parent rather than in-house drug discovery. It earns by selling branded oncology, cardiovascular/renal/metabolic, respiratory/immunology and rare-disease therapies through hospitals, oncologists, cardiologists and other specialist physicians across India. The company closed its domestic manufacturing plant during FY24-25 as part of a strategic shift toward a specialist, launch-led, import/marketing-driven model rather than local production. It also runs patient-access, early-diagnosis and disease-awareness partnerships (with hospitals, government health departments and diagnostic labs) to support uptake of its therapies.

Segments

  • Oncology
  • Biopharmaceuticals
  • Rare Disease
Indian Pharmaceutical Market (IPM) rank
#40 among IPM companies
Oncology brand market position
No.1 lung cancer brand (Tagrisso) and No.1 ovarian cancer brand in India
New medicine and indication approvals since 2023
14
Domestic manufacturing footprint
No domestic manufacturing plant (closed in FY24-25); operates an import/marketing-led commercial model
Precision Clinics network for severe-asthma diagnosis
200+ clinics established
Centres of Excellence (COEs) developed
10
Company website

Your own record

Start an Inve Case for AstraZeneca Pharma India Limited

Free account: one company. Everything above stays public.

Write why you follow AstraZeneca Pharma India Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse AstraZeneca Pharma India Limited

Guides on how to read this kind of business and the numbers that matter.